Background: We relied on the most contemporary Surveillance, Epidemiology, and End Results (SEER) database and tested the hypothesis that chemotherapy may improve survival in metastatic urachal carcinoma (m-UraC).

Material And Methods: Within the SEER database (2004-2016), we identified m-UraC patients aged ≥ 18 years. Propensity score matching (PSM: cystectomy status, age and sex), Kaplan-Meier plots, cumulative incidence plots, Cox regression models and competing risks regression (CRR) models addressed overall mortality (OM) and cancer-specific mortality (CSM).

Results: Overall, 274 m-UraC patients were identified with a median age of 70 years. Most were male (66%) and Caucasian (72%). Overall, 32% received chemotherapy. Chemotherapy-exposed patients were younger (62 vs. 73 years, p<0.001) and more frequently underwent cystectomy (19 vs. 8%, P = 0.014). In 274 m-UraC patients, median OM and CSM were 6 (4 -10) months and 8 (6 -14) months, respectively. After 1:1 PSM, chemotherapy-exposed patients exhibited lower OM (median 16 vs. 3 months; multivariable HR 0.38, P <0.001) and lower CSM (median 17 vs. 4 months; multivariable CRR HR 0.52, P = 0.001). The association between chemotherapy and better survival was even stronger in younger (≤70 years) patients (OM HR: 0.23, P <0.001; CSM CRR HR: 0.42, P = 0.001), but not in older (≥71 years) patients (OM HR: 0.61, P = 0.2; CSM CRR HR: 1.02, P = 1), after PSM and multivariable adjustments.

Conclusion: Overall, we validated the very aggressive nature of UraC, when distant metastases are present, and observed that m-UraC patients exposed to chemotherapy exhibited lower OM and CSM.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2021.09.008DOI Listing

Publication Analysis

Top Keywords

metastatic urachal
8
urachal carcinoma
8
seer database
8
m-urac patients
8
survival benefit
4
benefit chemotherapy
4
chemotherapy contemporary
4
contemporary cohort
4
cohort metastatic
4
carcinoma background
4

Similar Publications

Congenital urachal and urinary bladder defects leading to uroperitoneum in a neonatal quarter horse colt.

Can Vet J

November 2024

Pilchuck Veterinary Hospital, Snohomish, Washington, USA (Karam); Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA (Arndt); Department of Surgical and Radiological Sciences (Magdesian) and Department of Medicine and Epidemiology (Dechant), School of Veterinary Medicine, University of California, Davis, California, USA; Equine Medical Center of Ocala, Ocala, Florida, USA (Cullen).

A newborn (5 h old) quarter horse colt was presented because of lethargy and severe abdominal distention. Uroperitoneum was suspected during initial workup, based on sonographic imaging and peritoneal fluid analysis. Definitive diagnosis was confirmed during exploratory celiotomy.

View Article and Find Full Text PDF
Article Synopsis
  • * Most urachal cancers are classified as intestinal adenocarcinomas (90%), and they often occur in the lower urachal tube or bladder dome, leading to late diagnoses due to the silent nature of early stages.
  • * Treatment options for this aggressive cancer include surgery and chemotherapy (like cisplatin), with some patients showing positive responses to targeted therapies; a case study highlighted successful surgical treatment for a patient with advanced disease.
View Article and Find Full Text PDF

Introduction: Urachal carcinomas are uncommon malignant neoplasms comprising only 0.01% of all adult cancers. Most patients were aged from 58 to 64 years at diagnosis with 60 years being the median.

View Article and Find Full Text PDF
Article Synopsis
  • * The case series discusses three elderly women with similar umbilical-related issues, highlighting the diagnostic challenges due to similarities with benign conditions.
  • * Accurate diagnosis requires integrating clinical findings, imaging results, and pathology, as seen in the differing outcomes: a Sister Mary Joseph nodule, liposarcoma, and an infected urachal cyst.
View Article and Find Full Text PDF

Of all primary bladder cancers, primary adenocarcinoma is an uncommon tumor. When considering all tumor origin areas, secondary bladder involvement from carcinoma, whether by direct extension or metastasis, is actually more prevalent than primary adenocarcinoma, despite its rarity. The most common source of subsequent bladder tumors is endometrial, lung, colon, prostate, breast, or other organ adenocarcinomas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!